BioSpace News Archive

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced it will release its third quarter 2023 financial and operating results on Monday, November 6, 2023, following the close of trading.

Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their participation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) occurring November 1-5, 2023 in San Diego, CA.

Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure, announced it has received whole-body MRI-conditional approval for the Optimizer® Smart Mini system from the United States Food and Drug Administration.

Porosome Therapeutics, Inc. has announced a new and distinctive therapy for Type 1 Diabetes and Type 2 Diabetes targeting the insulin secretory defects founds in beta cells associated with the disease.

A report published in the Association for Diagnostics & Laboratory Medicine’s The Journal of Applied Laboratory Medicine describes the strategies used by the National Basketball Association to limit COVID-19 exposure among the individuals who participated in the 2019–2020 season.

Angstrom Technology is thrilled to announce a new addition to its world class leadership team with the hiring of Jennifer Biro in role of President for its newly formed Life Sciences Division.

Sebela Women’s Health Inc., a part of Sebela Pharmaceuticals, today announced additional positive data from the pivotal Phase 3 open-label study of the investigational Copper 175 mm2 intra-uterine device (IUD).

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that Stem Cell Research & Therapy published the Company’s seventh peer reviewed study of ACP-01 - the third peer reviewed study of ACP-01 as a treatment for heart disease

Stryker (NYSE:SYK) will participate in the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023 at the Kimpton EPIC Hotel in Miami, Florida.

Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, reported third quarter 2023 financial results and business highlights.